SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

OSUR

OraSure Technologies, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed7d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Revenue growth is accelerating (14% YoY) and gross margins are expanding, but the company remains unprofitable with GAAP and non-GAAP losses. The Q4 guidance midpoint of $31M implies flat sequential revenue. Watch for the trajectory of operating leverage and cash burn in the next quarter, as well as the ramp of new product launches (Colli-Pee Dx, OraQuick Ebola 2.0) into 2027.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$3.33
T+0 close · Nov 9, 2026 · via day close
Latest settled
+6.91%
T+1 · $3.56 · next T+5 in 4h
Vs SPY
+5.59%
α at T+1
Latest observation
+11.37%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $3.33entry
  2. T+1 · 6d ago +6.91%α +5.59% · $3.56
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

OraSure reported Q3 2026 revenue of $30.9M, up 14% YoY and 1% sequentially, beating the $31.0M consensus. GAAP EPS was -$0.19, slightly worse than the -$0.18 consensus, while non-GAAP EPS was -$0.15. Core business revenue grew 14% YoY, gross margin improved 170 bps to 45.2%, and the company guided Q4 revenue of $30M-$32M, implying full-year growth of ~4.7%.

Key Financial Metrics

EPS
−$0.19
est −$0.18 · -5.6%
Revenue
$30.9M
est $31.0M · -0.3% · +14.1% YoY
Rating
miss
Guidance
$30.0M-$32.0M
maintained
Free Cash Flow
-$39.7M
Gross Margin
45.2%

Key Facts

  • Q3 2026 total net revenue $30.9M, up 14% YoY and 1% sequentially
  • GAAP EPS -$0.19 vs consensus -$0.18 (miss by $0.01)
  • Non-GAAP EPS -$0.15 vs prior year -$0.13
  • Core business revenue (ex-COVID and Risk Assessment) $30.9M, up 14% YoY
  • Diagnostics revenue $16.8M, up 16% YoY; Sample Management Solutions $12.5M, up 21% YoY
  • GAAP gross margin 45.2%, up 170 bps YoY from 43.5%
  • GAAP operating loss improved to $13.0M from $16.1M YoY
  • Cash and equivalents $148M as of Sep 30, 2026, down from $199M at Dec 31, 2025
  • Q4 2026 revenue guidance $30M-$32M
  • Initial orders received for Colli-Pee Dx and OraQuick Ebola 2.0 in Q3

Financial Impact

Revenue beat consensus by $0.1M (0.3%), EPS missed by $0.01 (5.6%); gross margin improved 170 bps; cash burn of $51M YTD

revenuegross marginoperating losscash

Segment Breakdown

SegmentRevenueGrowth
Diagnostics$16.8M+16.0%
Sample Management Solutions$12.5M+21.0%
Other products and services$771.0K+74.0%
COVID-19 Diagnostics$22.0K-75.0%
Risk Assessment Testing$0.00Not reported

Risk Factors

  • Continued GAAP and non-GAAP net losses with no near-term profitability timeline
  • Cash burn of $51M YTD, cash down to $148M from $199M at year-end 2025
  • Revenue guidance for Q4 implies only ~4.7% full-year growth, below the 14% Q3 growth rate
  • Dependence on new product adoption (Colli-Pee Dx, OraQuick Ebola 2.0) for future growth

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398945

Track record

20 reports on OSUR

Performance horizon

6 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +39.73% at T+60 after the Mar 13, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 10-Q/A Neutral 2/10 Entry $3.62 to $3.62 Now $3.60 −0.55% · 0.00% +0.36% vs SPY
  2. Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $3.33 to $3.56 Now $3.60 +8.11% ▲ +6.91% +5.59% vs SPY
  3. Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $3.53 to $3.33 Now $3.60 +1.98% ▼ −5.67% −5.30% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $3.46 to $3.53 Now $3.60 +4.20% ▲ +2.17% +1.87% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $3.94 to $3.46 Now $3.60 −8.63% ▼ −12.31% −11.83% vs SPY
  6. Sep 17, 20268w ago SC 13D Bullish 6/10 Entry $3.56 to $3.69 Now $3.60 +1.12% ▲ +3.65% +2.10% vs SPY
  7. Jul 23, 202616w ago Court Ruling Neutral 3/10 Entry $3.97 to $3.96 Now $3.60 −9.32% ▼ −0.25% −0.27% vs SPY
  8. Jun 12, 202622w ago Institutional Cluster Mixed 4/10 Entry $4.18 to $4.17 Now $3.60 −13.88% ▼ −0.24% −2.00% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 3/10 Entry $4.17 to $4.04 Now $3.60 −13.67% ▼ −3.12% −0.52% vs SPY
  10. May 6, 202627w ago 8-K Bearish 6/10 Entry $3.13 to $3.06 Now $3.60 −15.02% ▲ +2.24% +3.07% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026